RxDoctor Payments Data

Steven Frucht, MD

Neurology · New York, NYNPI 1336157130

Payments from drug & device makers

$55,837in general payments, 2019–2025

Across 10 payments — averaging $5583.66 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Eli Lilly$29K
  • Merz Pharmaceuticals, LLC$24K
  • Orphalan Inc$2K
  • Neurocrine Biosciences, Inc.$2K
  • Medtronic$77
  • Lundbeck LLC$65
  • plus $78 from 2 others

What the payments were for

  • Consulting fees$1,50043%
  • Speaking & faculty fees$1,80051%
  • Food & beverage$2206%

General payments by program year

19
20
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Eli Lilly3$28,785
Merz Pharmaceuticals, LLC1$23,532
Orphalan Inc1$1,800
Neurocrine Biosciences, Inc.1$1,500
Medtronic1$77
Lundbeck LLC1$65
Kyowa Kirin, Inc.1$54
Abbott1$24

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$55,837 in reported general payments places this provider in the 80th percentile of 1,623 neurology providers in New York.

See all neurology providers in New York

Medicare billing

Part B allowed, 2024
$576,851
Medicare patients
893
Services billed
49,706

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
IngrezzaValbenazine Tosylate25$206,898
GocovriAmantadine Hcl29$101,622
OngentysOpicapone42$49,828
BotoxOnabotulinumtoxina25$25,362
NeuproRotigotine15$23,825
Carbidopa-LevodopaCarbidopa/Levodopa649$19,995
Carbidopa-Levodopa ErCarbidopa/Levodopa245$13,137
RytaryCarbidopa/Levodopa12$9,732
Entacapone45$9,156
Rasagiline Mesylate31$7,079
Carbidopa22$6,812
Carbidopa-Levodopa-EntacaponeCarbidopa/Levodopa/Entacapone11$3,270
Midodrine Hcl30$2,734
Clozapine59$2,474
AmantadineAmantadine Hcl48$2,384

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Neurocrine Biosciences, Inc.Ingrezza, Ongentys$1,500$256,72767 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 1,623 neurology providers in New York.

Other neurology in New York

See the full list for New York

Where these figures come from

Is this you, or does something look wrong? →